CLAIMS

1. Use of deutetrabenazine in the manufacture of a medicament for treating chorea associated with Huntington's disease in a human transitioning from an existing daily amount of tetrabenazine for treating chorea associated with Huntington's disease to deutetrabenazine, the use comprising:

   a. discontinuing the daily amount of tetrabenazine;

   b. the next day, an initial daily amount of deutetrabenazine is to be administered to the human;

   wherein the daily amount of tetrabenazine is 12.5 mg and the initial total daily amount of deutetrabenazine is 6 mg; or

   wherein the daily amount of tetrabenazine is 25 mg and the initial total daily amount of deutetrabenazine is 12 mg; or

   wherein the daily amount of tetrabenazine is 37.5 mg and the initial total daily amount of deutetrabenazine is 18 mg; or

   wherein the daily amount of tetrabenazine is 50 mg and the initial total daily amount of deutetrabenazine is 24 mg; or

   wherein the daily amount of tetrabenazine is 62.5 mg and the initial total daily amount of deutetrabenazine is 30 mg; or

   wherein the daily amount of tetrabenazine is 75 mg and the initial total daily amount of deutetrabenazine is 36 mg; or

   wherein the daily amount of tetrabenazine is 87.5 mg and the initial total daily amount of deutetrabenazine is 42 mg; or

   wherein the daily amount of tetrabenazine is 100 mg and the initial total daily amount of deutetrabenazine is 48 mg.

2. The use of claim 1, wherein the transitioning results in the chorea control is improved by a reduction of at least 0.5 points on the Total Maximal Chorea (TMC) score.

3. The use of claim 2, wherein the improvement is measured from a pre-treatment, baseline to maintenance therapy.

4. The use of claim 1, wherein the transitioning results in a reduction of chorea by at least 15%.

5. The use of claim 1, wherein:

(i) the transitioning results in a reduction of chorea by at least 10% and said use also provides at least one of the following:

motor function is improved by at least 10%;

the human's physical functioning is improved;

swallowing is improved;

balance is not worsened;

treatment causes no significant increase in insomnia, depression, anxiety, agitation, suicidal ideation, akathisia, irritability, fatigue, parkinsonism or dysphagia;

the maximal increases in QTcF is less than 5 ms;

or combinations thereof; or

(ii) motor function is improved by at least 10%, and said use also provides at least one of the following:

chorea is reduced by at least 10% ;

the human's physical functioning is improved;

swallowing is improved;

balance is not worsened;

treatment causes no significant increase in insomnia, depression, anxiety, agitation, suicidal ideation, akathisia, irritability, fatigue, parkinsonism or dysphagia;

the maximal increases in QTcF is less than 5 ms;

or combinations thereof.

6. The use of claim 1, wherein the initial daily amount is 12 mg, 18 mg, 24 mg, 30 mg, 36 mg, 42 mg, or 48 mg and the initial daily amount is to be administered in two doses.

7. The use of claim 6, wherein:

the first dose is 6 mg and the second dose is 6 mg;

the first dose is 9 mg and the second dose is 9 mg;
the first dose is 12 mg and the second dose is 12 mg;
the first dose is 15 mg and the second dose is 15 mg;
the first dose is 18 mg and the second dose is 18 mg;
the first dose is 21 mg and the second dose is 21 mg; or
the first dose is 24 mg and the second dose is 24 mg.

8. The use of claim 7, further comprising:
   c) after about one week, determining the degree of control of abnormal involuntary movement achieved with the initial daily amount of the deutetrabenazine and the tolerability of the initial daily amount of the deutetrabenazine; and
   d) increasing the daily amount of the deutetrabenazine upward by 6 mg/day to a subsequent daily amount of the deutetrabenazine if the transitioning does not result in at least a maintenance of chorea control and the initial daily amount is tolerable.

9. The use of claim 8, further comprising:
   e) after about one week, repeating steps c) and d) in those humans wherein abnormal involuntary movement is reduced and the daily amount of deutetrabenazine is tolerated.

10. The use of claim 9, further comprising:
    decreasing the amount of deutetrabenazine by 6 mg/day to a subsequent daily amount in those humans wherein any subsequent daily amount is not tolerated.

11. The use of claim 9, further comprising repeating step e) until the degree of control of abnormal involuntary movement is adequate and the daily amount of deutetrabenazine is tolerable.

12. The use of claim 1, wherein the initial daily amount is 6 mg and is to be administered in one dose.

13. The use of claim 1, wherein the initial daily amount of deutetrabenazine is 6 mg, 12 mg, 18 mg, 24 mg, 30 mg, 36 mg, or 42 mg, further comprising:

c) after about one week, determining the degree of control of abnormal involuntary movement achieved with the initial daily amount of the deutetrabenazine and the tolerability of the initial daily amount of the deutetrabenazine; and

d) increasing the daily amount of the deutetrabenazine by 6 mg/day to a subsequent daily amount in those humans wherein the transitioning does not result in at least a maintenance of chorea control and the initial daily amount is tolerable.

14. The use of claim 13, wherein the subsequent daily amount is 12 mg, 18 mg, 24 mg, 30 mg, 36 mg, or 42 mg, further comprising:

e) after about one week, repeating steps c) and d) in those humans wherein abnormal involuntary movement is reduced and the daily amount of deutetrabenazine is tolerated.

15. The use of claim 14, wherein the daily amount is 18 mg, 24 mg, 30 mg, 36 mg, or 42 mg, further comprising repeating step e) until the degree of control of abnormal involuntary movement is adequate and the daily amount of deutetrabenazine is tolerable.

16. The use of claim 15, wherein the total maximum daily dose is 48 mg.

17. The use of claim 15, where in the total maximum daily dose is 36 mg.

18. The use of claim 17, wherein the human is concurrently receiving a strong CYP2D6 inhibitor.

19. The use of claim 18, wherein the strong CYP2D6 inhibitor is fluoxetine, paroxetine, bupropion, quinidine, cinacalcet, or ritonavir.

20. The use of claim 19, wherein the strong CYP2D6 inhibitor is paroxetine, fluoxetine, or bupropion.

21. The use of claim 1, wherein the daily amount of tetrabenazine is 12.5 mg and the initial total daily amount of deutetrabenazine is 6 mg.

22. The use of claim 1, wherein the daily amount of tetrabenazine is 25 mg and the initial total daily amount of deutetrabenazine is 12 mg.

23. The use of claim 22, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 6 mg and the second dose is 6 mg.

24. The use of claim 1, wherein the daily amount of tetrabenazine is 37.5 mg and the initial total daily amount of deutetrabenazine is 18 mg.

25. The use of claim 24, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 9 mg and the second dose is 9 mg.

26. The use of claim 1, wherein the daily amount of tetrabenazine is 50 mg and the initial total daily amount of deutetrabenazine is 24 mg.

27. The use of claim 26, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 12 mg and the second dose is 12 mg.

28. The use of claim 1, wherein the daily amount of tetrabenazine is 62.5 mg and the initial total daily amount of deutetrabenazine is 30 mg.

29. The use of claim 28, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 15 mg and the second dose is 15 mg.

30. The use of claim 1, wherein the daily amount of tetrabenazine is 75 mg and the initial total daily amount of deutetrabenazine is 36 mg.

31. The use of claim 30, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 18 mg and the second dose is 18 mg.

32. The use of claim 1, wherein the daily amount of tetrabenazine is 87.5 mg and the initial total daily amount of deutetrabenazine is 42 mg.

33. The use of claim 32, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 21 mg and the second dose is 21 mg.

34. The use of claim 1, wherein the daily amount of tetrabenazine is 100 mg and the initial total daily amount of deutetrabenazine is 48 mg.

35. The use of claim 34, wherein the initial total daily amount of deutetrabenazine is to be administered in two doses, wherein the first dose is 24 mg and the second dose is 24 mg.

36. The use of claim 1, wherein the transitioning results in at least a maintenance of chorea control in the human.

37. The use of claim 1, wherein the initial total daily amount of deutetrabenazine is 6 mg, 12 mg, 18 mg, 24 mg, 30 mg, or 36 mg.

38. The use of claim 37, wherein the human is concurrently receiving a strong CYP2D6 inhibitor.

39. The use of claim 38, wherein the strong CYP2D6 inhibitor is fluoxetine, paroxetine, bupropion, quinidine, cinacalcet, or ritonavir.

40. The use of claim 38, wherein the strong CYP2D6 inhibitor is paroxetine, fluoxetine, or bupropion.

41. Use of deutetrabenazine in the manufacture of a medicament for treating abnormal involuntary movements in a human subject having Tardive Dyskinesia;
wherein if the subject is male, the subject does not have a QTcF value > 450 ms on a 12-lead electrocardiogram (ECG) at baseline; or
wherein if the subject is female, the subject does not have a QTcF value > 460 ms on a 12-lead electrocardiogram (ECG) at baseline;
wherein said deutetrabenazine is to be administered at a dose of less than or equal to about 24 mg;
wherein the administration results in an improvement in motor function in the subject, as compared to the subject's motor function prior to the administration, and a maximal increase in the subject's QTcF of less than 5 ms.

42. The use of claim 41, wherein the subject is to be administered a total daily amount of deutetrabenazine in two doses.

43. The use of claim 42, wherein the total daily amount of deutetrabenazine is less than or equal to 48 mg.

44. The use of claim 42, wherein the total daily amount of deutetrabenazine is less than or equal to 42 mg.

45. The use of claim 42, wherein the total daily amount of deutetrabenazine is less than or equal to 36 mg.

46. The use of claim 45, wherein the subject is concurrently receiving a strong CYP2D6 inhibitor.

47. The use of claim 46, wherein the strong CYP2D6 inhibitor is fluoxetine, paroxetine, bupropion, quinidine, cinacalcet, or ritonavir.

48. The use of claim 46, wherein the strong CYP2D6 inhibitor is paroxetine, fluoxetine, or bupropion.

49. The use of claim 41, resulting in no clinically significant adverse event in the subject.

50. The use of claim 41, wherein the improvement in motor function is a reduction in the severity of abnormal involuntary movements, as measured by the Abnormal Involuntary Movement Scale.

51. The use of claim50, wherein the improvement is a 10% reduction in Abnormal Involuntary Movement Scale score.

52. The use of claim50 , wherein the improvement is a 50% reduction in Abnormal Involuntary Movement Scale score.

53.The use of claim50 , wherein the improvement is a 90% reduction in Abnormal Involuntary Movement Scale score.

54. The use of claim 41, wherein the improvement in motor function is measured by the Clinical Global Impression of Change or the modified Craniocervical Dystonia score.

55. The use of claim 49, resulting in no significant increase in insomnia, depression, anxiety, agitation, suicidal ideation, akathisia, irritability, fatigue parkinsonism or dysphagia in the subject.

56. The use of claim 41, further comprising another therapeutic agent useful in the treatment of VMAT2-mediated disorders to be administered in the subject.

57. The use of claim 41, further comprising a dopamine receptor antagonist with the deutetrabenazine to be concomitantly administered in the subject.

58. The use of claim 41, wherein the subject is an adult.

59. The use of claim 41, wherein the subject is at least 18 years of age.

60. The use of claim 42, wherein the total daily amount of deutetrabenazine is to be administered in two equal doses.

61. The use of claim 42, wherein the total daily amount of deutetrabenazine is from about 24 mg to about 48 mg.

62. The use of claim 42, wherein the total daily amount of deutetrabenazine is from about 36 mg to about 48 mg.

63. The use of claim 42, wherein the total daily amount of deutetrabenazine is from about 24 mg to about 36 mg.

64. The use of claim 41, wherein

a) the subject is to be administered an initial daily amount of deutetrabenazine in two doses.

65. The use of claim 64, wherein:

the first dose is about 6 mg and the second dose is about 6 mg;

the first dose is about 9 mg and the second dose is about 9 mg;

the first dose is about 12 mg and the second dose is about 12 mg.

66. The use of claim 64, wherein the first dose is about 6 mg and the second dose is about 6 mg.

67. The use of claim 65, further comprising:

b) determining after about one week, the degree of control of abnormal involuntary movement achieved with the initial daily amount of the deutetrabenazine and the tolerability of the initial daily amount of the deutetrabenazine; and

c) increasing the daily amount of the deutetrabenazine upward by 6 mg/day to a subsequent daily amount if the degree of control of abnormal involuntary movement is inadequate and the initial daily amount is tolerable.

68. The use of claim 67, further comprising after about one week, repeating steps b) and c) provided that abnormal involuntary movement is reduced and the daily amount of deutetrabenazine is tolerated.

69. The use of claim 67, wherein if the subsequent daily amount is not tolerated, decreasing the amount of deutetrabenazine downward by 6 mg/day to a subsequent daily amount.

70. The use of claim 64, further comprising:

d) repeating steps b) and c) until the degree of control of abnormal involuntary movement is adequate and the daily amount of the deutetrabenazine is tolerable; and

e) if any subsequent amount of deutetrabenazine is intolerable, decreasing the daily amount downward by 6 or more mg/day to another subsequent daily amount of deutetrabenazine.

71. The use of claim 41, resulting in no significant increase in depression or suicidal ideation.

72. Use of deutetrabenazine in the manufacture of a medicament for treating abnormal involuntary movements in a human subject having Tardive Dyskinesia;

wherein the subject is sixty years of age or older, and has a history of dopamine receptor antagonist use for at least one month;

or wherein the subject is not sixty years of age or older, and has a history of dopamine receptor antagonist use for at least three months; wherein the medicament comprising:

one or two doses, a total daily amount of the deutetrabenazine of from about 24 mg to about 48 mg;

wherein the administration results in an improvement in motor function in the subject, as compared to the subject's motor function prior to the administration, and no clinically significant adverse event.

73. The use of claim 72, wherein the total daily amount of deutetrabenazine is 24 mg.

74.The use of claim 72, wherein the total daily amount of deutetrabenazine is 42 mg.

75. The use of claim 72, wherein the total daily amount of deutetrabenazine is 36 mg.

76. The use of claim 72, wherein the total daily amount of deutetrabenazine is to be administered in two doses.

77. The use of claim 72, wherein the total daily amount of deutetrabenazine is from about 24 mg to about 36 mg.

78. The use of claim 77, wherein the subject is concurrently receiving a strong CYP2D6 inhibitor.

79.The use of claim 78, wherein the strong CYP2D6 inhibitor is fluoxetine, paroxetine, bupropion, quinidine, cinacalcet, or ritonavir.

80. The use of claim 78, wherein the strong CYP2D6 inhibitor is paroxetine, fluoxetine, or bupropion.

81. The use of claim 72, wherein the improvement in motor function is a reduction in the severity of abnormal involuntary movements, as measured by the Abnormal Involuntary Movement Scale.

82. The use of claim 81, wherein the improvement is a 10% reduction in Abnormal Involuntary Movement Scale score.

83. The use of claim 81, wherein the improvement is a 50% reduction in Abnormal Involuntary Movement Scale score.

84. The use of claim 81, wherein the improvement is a 90% reduction in Abnormal Involuntary Movement Scale score.

85. The use of claim 72, wherein the improvement in motor function is measured by the Clinical Global Impression of Change or the modified Craniocervical Dystonia score.

86. The use of claim 72, resulting in no significant increase in insomnia, depression, anxiety, agitation, suicidal ideation, akathisia, irritability, fatigue, parkinsonism or dysphagia in the subject.

87. The use of claim 72, further comprising another therapeutic agent useful in the treatment of VMAT2-mediated disorders to be administered in the subject.

88. The use of claim72, wherein the dopamine receptor antagonist is to be administered concomitantly with the deutetrabenazine.

89. The use of claim 72, wherein the subject is an adult.

90. The use of claim 72, wherein the subject is at least 18 years of age.

91. The use of claim 72, wherein the total daily amount of deutetrabenazine is 30 mg.

92. The use of claim 72, wherein the total daily amount of deutetrabenazine is 48 mg.

93. The use of claim 72, resulting in no significant increase in depression or suicidal ideation.